Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1

Coronary Artery Disease

Volumn 19, Issue 5, 2008, Pages 355-361

  Sato, Yuki ^a   Dong, Jie ^a   Imagawa, Shogo ^a   Ishimori, Naoki ^a   Furumoto, Tomoo ^a   Tsutsui, Hiroyuki ^a   Sobel, Burton E ^b   Fujii, Satoshi ^a,c  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF VERMONT   (United States)

^c NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Cardiovascular risk; Insulin; Liver; Plasminogen activator inhibitor type 1; Statins

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 HYDROXY 3 ETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; C57BL MOUSE; CULTURE MEDIUM; FIBRINOLYSIS; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; ENZYME INHIBITORS; FIBRINOLYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN;

EID: 58149109143     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328300dbe3     Document Type: Article

References (35)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002; 288:2709-2716.
2. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn study. Circulation 2005; 112:666-673.
3. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801.
4. Sobel BE. The potential influence of insulin and plasminogen activator inhibitor type-1 on formulation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Phys 1999; 111:313-318.
5. Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563.
6. Sobel BE, Schneider DJ, Lee YH, Pratley RE. Insulin resistance increases PAI-1 in the heart. Biochem Biophys Res Commun 2006; 346:102-107.
7. Sobel BE, Lee YH, Pratley RE, Schneider DJ. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. Life Sci 2006; 79:1600-1605.
8. Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 2004; 255:448-456.
9. Alessi MC, Lijnen HR, Bastelica D, Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2003; 33:290-297.
10. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50:1844-1850.
11. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003; 23:1262-1268.
12. Corsini A, Ferri N, Cortellaro M. Are pleiotropic effects of statins real? Vasc Health Risk Manag 2007; 3:611-613.
13. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type II: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad U S A 1991; 88:9959-9963.
14. Imagawa S, Fujii S, Dong J, Furumoto T, Kaneko T, Zaman T, et al. Hepatocyte growth factor regulates E box-dependent plasminogen activator inhibitor type 1 gene expression in HepG2 liver cells. Arterioscler Thromb Vasc Biol 2006; 26:2407-2413.
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
16. Kooptiwut S, Zraika S, Thorburn AW, Dunlop ME, Darwiche R, Kay TW, et al. Comparison of insulin secretory function in two mouse models with different susceptibility to β-cell failure. Endocrinology 2002; 143:2085-2092.
17. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004; 53:1060-1067.
18. Ma K, Cabrero A, Saha PK, Kojima H, Li L, Chang BHJ, et al. Increaced b-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002; 277:34658-34661.
19. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, et al. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005; 54:3530-3540.
20. Minami A, Iseki M, Kishi K, Wang M, Ogura M, Hukukawa N, et al. Increased insulin sensitivity and hypoinsulinemia in APS knockout mice. Diabetes 2003; 52:2657-3665.
21. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamp in the conscious mouse. Diabetes 2006; 55:390-397.
22. Dong J, Fujii S, Goto D, Furumoto T, Kaneko T, Zaman T, et al. Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives. Hypertens Res 2003; 26:723-729.
23. Dong J, Fujii S, Li H, Nakabayashi H, Sakai M, Nishi S, et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-δ. Arterioscler Thromb Vasc Biol 2005; 25:1078-1084.
24. Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 2000; 85:1563-1568.
25. Venugopal J, Hanashiro K, Yang ZZ, Nagamine Y. Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc Natl Acad Sci U S A 2004; 101:17120-17125.
26. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007; 104:470-479.
27. Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/protein kinase akt negatively regulates plasminogen activator inhibitor type-1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2007; 292:H1937-H1942.
28. Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 2007; 35:1725-1729.
29. Kaneko T, Fujii S, Matsumoto A, Goto D, Ishimori N, Watano K, et al. Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid. Arterioscler Thromb Vasc Biol 2002; 22:855-860.
30. Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93:106-110.
31. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993; 72:413-421.
32. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 2006; 6:47-54.
33. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99:2496-2498.
34. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 1996; 7:813-817.
35. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93:1073-1078.